Olaparib is the first cancer drug to target inherited genetic mutations . 
  The drug already works for women with breast cancer fuelled by BRCA gene mutations . 
  Up to 30 per cent of men with advanced prostate cancer have tumours that have DNA defects . 
  Clinical trials show the drug can delay the moment when the disease gets dangerously out of control . 
 